-
1
-
-
65749117793
-
Nanoparticle interaction with plasma proteins as it relates to particle biodistribution, biocompatibility and therapeutic efficacy
-
Aggarwal P, Hall JB, Mcleland CB, Dobrovolskaia MA, McNeil SE. Nanoparticle interaction with plasma proteins as it relates to particle biodistribution, biocompatibility and therapeutic efficacy. Adv Drug Deliv Rev, 2009;61:428-37.
-
(2009)
Adv Drug Deliv Rev
, vol.61
, pp. 428-437
-
-
Aggarwal, P.1
Hall, J.B.2
Mcleland, C.B.3
Dobrovolskaia, M.A.4
McNeil, S.E.5
-
2
-
-
84860231453
-
Do inhaled corticosteroid/long-acting beta2-agonist fixed combinations provide superior clinical benefits compared with separate inhalers? A literature reappraisal
-
Barnes PJ, Nicolini G, Bizzi A, Spinola M, Singh D. Do inhaled corticosteroid/long-acting beta2-agonist fixed combinations provide superior clinical benefits compared with separate inhalers? A literature reappraisal. Allergy Asthma Proc, 2012;33:140-4.
-
(2012)
Allergy Asthma Proc
, vol.33
, pp. 140-144
-
-
Barnes, P.J.1
Nicolini, G.2
Bizzi, A.3
Spinola, M.4
Singh, D.5
-
3
-
-
77049160936
-
PAS inhalation therapy of respiratory tuberculosis in the sanatorium LIBANI; preliminary communication
-
Berishvili TA. PAS inhalation therapy of respiratory tuberculosis in the sanatorium LIBANI; preliminary communication. Probl Tuberk, 1954;4:69-70.
-
(1954)
Probl Tuberk
, vol.4
, pp. 69-70
-
-
Berishvili, T.A.1
-
4
-
-
84858997919
-
Preclinical evidence for implementing a prime-boost vaccine strategy for tuberculosis
-
Brennan MJ, Clagett B, Fitzgerald H, Chen V, Williams A, Izzo AA, Barker LF. Preclinical evidence for implementing a prime-boost vaccine strategy for tuberculosis. Vaccine, 2012;30:2811-23.
-
(2012)
Vaccine
, vol.30
, pp. 2811-2823
-
-
Brennan, M.J.1
Clagett, B.2
Fitzgerald, H.3
Chen, V.4
Williams, A.5
Izzo, A.A.6
Barker, L.F.7
-
5
-
-
0034455173
-
Preventing tuberculosis with bacillus Calmette-Guerin vaccine: A meta-analysis of the literature
-
Brewer TF. Preventing tuberculosis with bacillus Calmette-Guerin vaccine: A meta-analysis of the literature. Clin Infect Dis, 2000;31:S64-7.
-
(2000)
Clin Infect Dis
, vol.31
, pp. S64-S67
-
-
Brewer, T.F.1
-
6
-
-
79951577062
-
Influence of particle size on regional lung deposition - what evidence is there?
-
Carvalho TC, Peters JI, Williams III RO. Influence of particle size on regional lung deposition - what evidence is there? Int J Pharm, 2011;406:1-10.
-
(2011)
Int J Pharm
, vol.406
, pp. 1-10
-
-
Carvalho, T.C.1
Peters, J.I.2
Williams, R.O.3
-
7
-
-
33847789142
-
Understanding the nanoparticle-protein corona using methods to quantify exchange rates and affinities of proteins for nanoparticles
-
Cedervall T, Lynch I, Lindman S, Berggard T, Thulin E, Nilsson H, Dawson KA, Linse S. Understanding the nanoparticle-protein corona using methods to quantify exchange rates and affinities of proteins for nanoparticles. Proc Natl Acad Sci USA, 2007;104:2050-5.
-
(2007)
Proc Natl Acad Sci USA
, vol.104
, pp. 2050-2055
-
-
Cedervall, T.1
Lynch, I.2
Lindman, S.3
Berggard, T.4
Thulin, E.5
Nilsson, H.6
Dawson, K.A.7
Linse, S.8
-
8
-
-
84873703779
-
A novel dry powder inhalable formulation incorporating three first-line anti-tubercular antibiotics
-
Chan JG, Chan HK, Prestidge CA, Denman JA, Young PM, Traini D. A novel dry powder inhalable formulation incorporating three first-line anti-tubercular antibiotics. Eur J Pharm Biopharm, 2012;83:285-92.
-
(2012)
Eur J Pharm Biopharm
, vol.83
, pp. 285-292
-
-
Chan, J.G.1
Chan, H.K.2
Prestidge, C.A.3
Denman, J.A.4
Young, P.M.5
Traini, D.6
-
9
-
-
0027407330
-
Respiratory tract uptake of inhalants and metabolism of xenobiotics
-
Dahl AR, Lewis JL. Respiratory tract uptake of inhalants and metabolism of xenobiotics. Annu Rev Pharmacol Toxicol, 1993;33:383-407.
-
(1993)
Annu Rev Pharmacol Toxicol
, vol.33
, pp. 383-407
-
-
Dahl, A.R.1
Lewis, J.L.2
-
10
-
-
84877855898
-
Phase I, single-dose, dose-escalating study of inhaled dry powder capreomycin: A new approach to therapy of drug-resistant tuberculosis
-
Dharmadhikari AS, Kabadi M, Gerety B, Hickey AJ, Fourie PB, Nardell E. Phase I, single-dose, dose-escalating study of inhaled dry powder capreomycin: A new approach to therapy of drug-resistant tuberculosis. Antimicrob Agents Chemother, 2013;57:2613-19.
-
(2013)
Antimicrob Agents Chemother
, vol.57
, pp. 2613-2619
-
-
Dharmadhikari, A.S.1
Kabadi, M.2
Gerety, B.3
Hickey, A.J.4
Fourie, P.B.5
Nardell, E.6
-
11
-
-
84861124193
-
Phase II dose-ranging trial of the early bactericidal activity of PA-824
-
Diacon AH, Dawson R, du Bois J, Narunsky K, Venter A, Donald PR, van Niekerk C, Erondu N, Ginsberg AM, Becker P, Spigelman MK. Phase II dose-ranging trial of the early bactericidal activity of PA-824. Antimicrob Agents Chemother, 2012;56:3027-31.
-
(2012)
Antimicrob Agents Chemother
, vol.56
, pp. 3027-3031
-
-
Diacon, A.H.1
Dawson, R.2
Du Bois, J.3
Narunsky, K.4
Venter, A.5
Donald, P.R.6
Van Niekerk, C.7
Erondu, N.8
Ginsberg, A.M.9
Becker, P.10
Spigelman, M.K.11
-
12
-
-
10744227569
-
Large porous particles for pulmonary drug delivery
-
Edwards DA, Hanes J, Caponetti G, Hrkach J, Ben-Jebria A, Eskew ML, Mintzes J, Deaver D, Lotan N, Langer R. Large porous particles for pulmonary drug delivery. Science, 1997;276:1868-71.
-
(1997)
Science
, vol.276
, pp. 1868-1871
-
-
Edwards, D.A.1
Hanes, J.2
Caponetti, G.3
Hrkach, J.4
Ben-Jebria, A.5
Eskew, M.L.6
Mintzes, J.7
Deaver, D.8
Lotan, N.9
Langer, R.10
-
13
-
-
77953459390
-
Drug delivery to the lung: Permeability and physicochemical characteristics of drugs as the basis for a pulmonary biopharmaceutical classification system (pBCS)
-
Eixarch H, Haltner-Ukomadu E, Beisswenger C, Bock U. Drug delivery to the lung: Permeability and physicochemical characteristics of drugs as the basis for a pulmonary biopharmaceutical classification system (pBCS). J Epithelial Biol Pharmacol, 2010;3:1-14.
-
(2010)
J Epithelial Biol Pharmacol
, vol.3
, pp. 1-14
-
-
Eixarch, H.1
Haltner-Ukomadu, E.2
Beisswenger, C.3
Bock, U.4
-
14
-
-
65249121913
-
CD4 and CD8 T cell responses to the M. Tuberculosis Ag85B-TB10.4 promoted by adjuvanted subunit, adenovector or heterologous prime boost vaccination
-
Elvang T, Christensen JP, Billeskov R, Thi Kim Thanh Hoang T, Holst P, Thomsen AR, Andersen P, Dietrich J. CD4 and CD8 T cell responses to the M. tuberculosis Ag85B-TB10.4 promoted by adjuvanted subunit, adenovector or heterologous prime boost vaccination. PLoS One, 2009;4:e5139.
-
(2009)
PLoS One
, vol.4
, pp. e5139
-
-
Elvang, T.1
Christensen, J.P.2
Billeskov, R.3
Thi Kim Thanh Hoang, T.4
Holst, P.5
Thomsen, A.R.6
Andersen, P.7
Dietrich, J.8
-
15
-
-
43349083052
-
Preparation and in vivo evaluation of a dry powder for inhalation of capreomycin
-
Fiegel J, Garcia-Contreras L, Thomas M, Verberkmoes J, Elbert K, Hickey A, Edwards D. Preparation and in vivo evaluation of a dry powder for inhalation of capreomycin. Pharm Res, 2008;25:805-11.
-
(2008)
Pharm Res
, vol.25
, pp. 805-811
-
-
Fiegel, J.1
Garcia-Contreras, L.2
Thomas, M.3
Verberkmoes, J.4
Elbert, K.5
Hickey, A.6
Edwards, D.7
-
16
-
-
0019860296
-
Whither short-course chemotherapy?
-
Fox W. Whither short-course chemotherapy? Br J Dis Chest, 1981;75:331-57.
-
(1981)
Br J Dis Chest
, vol.75
, pp. 331-357
-
-
Fox, W.1
-
17
-
-
34547642167
-
Inhaled large porous particles of capreomycin for treatment of tuberculosis in a guinea pig model
-
Garcia-Contreras L, Fiegel J, Telko M, Elbert K, Hawi A, Thomas M, Verberkmoes J, Germishuizen W, Fourie P, Hickey A, Edwards D. Inhaled large porous particles of capreomycin for treatment of tuberculosis in a guinea pig model. Antimicrob Agents Chemother, 2007;51:2830-6.
-
(2007)
Antimicrob Agents Chemother
, vol.51
, pp. 2830-2836
-
-
Garcia-Contreras, L.1
Fiegel, J.2
Telko, M.3
Elbert, K.4
Hawi, A.5
Thomas, M.6
Verberkmoes, J.7
Germishuizen, W.8
Fourie, P.9
Hickey, A.10
Edwards, D.11
-
18
-
-
84860109542
-
Pharmacokinetics of sequential doses of capreomycin powder for inhalation in guinea pigs
-
Garcia-Contreras L, Muttil P, Fallon JK, Kabadi M, Gerety R, Hickey AJ. Pharmacokinetics of sequential doses of capreomycin powder for inhalation in guinea pigs. Antimicrob Agents Chemother, 2012;56:2612-18.
-
(2012)
Antimicrob Agents Chemother
, vol.56
, pp. 2612-2618
-
-
Garcia-Contreras, L.1
Muttil, P.2
Fallon, J.K.3
Kabadi, M.4
Gerety, R.5
Hickey, A.J.6
-
19
-
-
77950101234
-
Dry powder PA-824 aerosols for treatment of tuberculosis in guinea pigs
-
Garcia-Contreras L, Sung JC, Muttil P, Padilla D, Telko M, Verberkmoes JL, Elbert KJ, Hickey AJ, Edwards DA. Dry powder PA-824 aerosols for treatment of tuberculosis in guinea pigs. Antimicrob Agents Chemother, 2010;54:1436-42.
-
(2010)
Antimicrob Agents Chemother
, vol.54
, pp. 1436-1442
-
-
Garcia-Contreras, L.1
Sung, J.C.2
Muttil, P.3
Padilla, D.4
Telko, M.5
Verberkmoes, J.L.6
Elbert, K.J.7
Hickey, A.J.8
Edwards, D.A.9
-
20
-
-
34247193128
-
Novel tobramycin inhalation powder in cystic fibrosis subjects: Pharmacokinetics and safety
-
Geller DE, Konstan MW, Smith J, Noonberg SB, Conrad C. Novel tobramycin inhalation powder in cystic fibrosis subjects: Pharmacokinetics and safety. Pediatr Pulmonol, 2007;42:307-13.
-
(2007)
Pediatr Pulmonol
, vol.42
, pp. 307-313
-
-
Geller, D.E.1
Konstan, M.W.2
Smith, J.3
Noonberg, S.B.4
Conrad, C.5
-
21
-
-
79551481328
-
Optimization of inhaled therapies for tuberculosis: The role of macrophages and dendritic cells
-
Gonzalez-Juarrero M, O'Sullivan MP. Optimization of inhaled therapies for tuberculosis: The role of macrophages and dendritic cells. Tuberculosis (Edinb), 2011;91:86-92.
-
(2011)
Tuberculosis (Edinb)
, vol.91
, pp. 86-92
-
-
Gonzalez-Juarrero, M.1
O'Sullivan, M.P.2
-
22
-
-
0027946051
-
The influence of age, diagnosis, and gender on proper use of metered-dose inhalers
-
Goodman DE, Israel E, Rosenberg M, Johnston R, Weiss ST, Drazen JM. The influence of age, diagnosis, and gender on proper use of metered-dose inhalers. Am J Respir Crit Care Med, 1994;150:1256-61.
-
(1994)
Am J Respir Crit Care Med
, vol.150
, pp. 1256-1261
-
-
Goodman, D.E.1
Israel, E.2
Rosenberg, M.3
Johnston, R.4
Weiss, S.T.5
Drazen, J.M.6
-
23
-
-
0032702726
-
The orphan human pregnane X receptor mediates the transcriptional activation of CYP3A4 by rifampicin through a distal enhancer module
-
Goodwin B, Hodgson E, Liddle C. The orphan human pregnane X receptor mediates the transcriptional activation of CYP3A4 by rifampicin through a distal enhancer module. Mol Pharmacol, 1999;56:1329-39.
-
(1999)
Mol Pharmacol
, vol.56
, pp. 1329-1339
-
-
Goodwin, B.1
Hodgson, E.2
Liddle, C.3
-
24
-
-
0032754284
-
The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin
-
Greiner B, Eichelbaum M, Fritz P, Kreichgauer HP, von Richter O, Zundler J, Kroemer HK. The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. J Clin Invest, 1999;104:147-53.
-
(1999)
J Clin Invest
, vol.104
, pp. 147-153
-
-
Greiner, B.1
Eichelbaum, M.2
Fritz, P.3
Kreichgauer, H.P.4
Von Richter, O.5
Zundler, J.6
Kroemer, H.K.7
-
25
-
-
84886513932
-
Pharmaceutical aerosols for the treatment and prevention of tuberculosis
-
Hanif SN, Garcia-Contreras L. Pharmaceutical aerosols for the treatment and prevention of tuberculosis. Front Cell Infect Microbiol, 2012;2:118.
-
(2012)
Front Cell Infect Microbiol
, vol.2
, pp. 118
-
-
Hanif, S.N.1
Garcia-Contreras, L.2
-
26
-
-
75549084815
-
Effect of particle shape on dry particle inhalation: Study of flowability, aerosolization, and deposition properties
-
Hassan MS, Lau RW. Effect of particle shape on dry particle inhalation: Study of flowability, aerosolization, and deposition properties. AAPS PharmSciTech, 2009;10:1252-62.
-
(2009)
AAPS PharmSciTech
, vol.10
, pp. 1252-1262
-
-
Hassan, M.S.1
Lau, R.W.2
-
27
-
-
84885849579
-
Dry powder antibiotic aerosol product development: Inhaled therapy for tuberculosis
-
Hickey AJ, Misra A, Fourie PB. Dry powder antibiotic aerosol product development: Inhaled therapy for tuberculosis. J Pharm Sci, 2013;102:3900-7.
-
(2013)
J Pharm Sci
, vol.102
, pp. 3900-3907
-
-
Hickey, A.J.1
Misra, A.2
Fourie, P.B.3
-
28
-
-
0029164891
-
In vitro and in vivo activities of the benzoxazinorifamycin KRM-1648 against Mycobacterium tuberculosis
-
Hirata T, Saito H, Tomioka H, Sato K, Jidoi J, Hosoe K, Hidaka T. In vitro and in vivo activities of the benzoxazinorifamycin KRM-1648 against Mycobacterium tuberculosis. Antimicrob Agents Chemother, 1995;39:2295-303.
-
(1995)
Antimicrob Agents Chemother
, vol.39
, pp. 2295-2303
-
-
Hirata, T.1
Saito, H.2
Tomioka, H.3
Sato, K.4
Jidoi, J.5
Hosoe, K.6
Hidaka, T.7
-
29
-
-
77349119814
-
Delivery of rifampicin-PLGA microspheres into alveolar macrophages is promising for treatment of tuberculosis
-
Hirota K, Hasegawa T, Nakajima T, Inagawa H, Kohchi C, Soma G, Makino K, Terada H. Delivery of rifampicin-PLGA microspheres into alveolar macrophages is promising for treatment of tuberculosis. J Control Release, 2010;142:339-46.
-
(2010)
J Control Release
, vol.142
, pp. 339-346
-
-
Hirota, K.1
Hasegawa, T.2
Nakajima, T.3
Inagawa, H.4
Kohchi, C.5
Soma, G.6
Makino, K.7
Terada, H.8
-
30
-
-
79960984396
-
Modelling inhaled particle deposition in the human lung - A review
-
Hofmann W. Modelling inhaled particle deposition in the human lung - A review. J Aerosol Sci, 2011;42:693-724.
-
(2011)
J Aerosol Sci
, vol.42
, pp. 693-724
-
-
Hofmann, W.1
-
31
-
-
46549090057
-
Delivery of ofloxacin to the lung and alveolar macrophages via hyaluronan microspheres for the treatment of tuberculosis
-
Hwang SM, Kim DD, Chung SJ, Shim CK. Delivery of ofloxacin to the lung and alveolar macrophages via hyaluronan microspheres for the treatment of tuberculosis. J Control Release, 2008;129:100-6.
-
(2008)
J Control Release
, vol.129
, pp. 100-106
-
-
Hwang, S.M.1
Kim, D.D.2
Chung, S.J.3
Shim, C.K.4
-
32
-
-
0345672746
-
Fifteen year follow up of trial of BCG vaccines in south India for tuberculosis prevention
-
Tuberculosis Research Centre (ICMR)
-
ICMR. Fifteen year follow up of trial of BCG vaccines in south India for tuberculosis prevention. Tuberculosis Research Centre (ICMR), Chennai. Indian J Med Res, 1999;110:56-69.
-
(1999)
Chennai. Indian J Med Res
, vol.110
, pp. 56-69
-
-
ICMR1
-
33
-
-
0028054999
-
Extrahepatic metabolism of drugs in humans
-
Krishna DR, Klotz U. Extrahepatic metabolism of drugs in humans. Clin Pharmacokinet, 1994;26:144-60.
-
(1994)
Clin Pharmacokinet
, vol.26
, pp. 144-160
-
-
Krishna, D.R.1
Klotz, U.2
-
34
-
-
0344513087
-
Pulmonary drug delivery. Part I: Physiological factors affecting therapeutic effectiveness of aerosolized medications
-
Labiris NR, Dolovich MB. Pulmonary drug delivery. Part I: Physiological factors affecting therapeutic effectiveness of aerosolized medications. Br J Clin Pharmacol, 2003;56:588-99.
-
(2003)
Br J Clin Pharmacol
, vol.56
, pp. 588-599
-
-
Labiris, N.R.1
Dolovich, M.B.2
-
35
-
-
41149173349
-
Synthesis and antitubercular activity of 7-(R)- and 7-(S)-methyl-2-nitro-6-(S)-(4-(trifluoromethoxy)benzyloxy)-6,7-dihydro-5H-imidazo [2,1-b][1,3]oxazines, analogues of PA-824
-
Li X, Manjunatha UH, Goodwin MB, Knox JE, Lipinski CA, Keller TH, Barry III CE, Dowd CS. Synthesis and antitubercular activity of 7-(R)- and 7-(S)-methyl-2-nitro-6-(S)-(4-(trifluoromethoxy)benzyloxy)-6,7-dihydro-5H-imidazo [2,1-b][1,3]oxazines, analogues of PA-824. Bioorg Med Chem Lett, 2008;18:2256-62.
-
(2008)
Bioorg Med Chem Lett
, vol.18
, pp. 2256-2262
-
-
Li, X.1
Manjunatha, U.H.2
Goodwin, M.B.3
Knox, J.E.4
Lipinski, C.A.5
Keller, T.H.6
Barry, C.E.7
Dowd, C.S.8
-
36
-
-
84875427854
-
Targeting the small airways asthma phenotype: If we can reach it, should we treat it?
-
Lipworth B. Targeting the small airways asthma phenotype: If we can reach it, should we treat it? Ann Allergy Asthma Immunol, 2013;110:233-9.
-
(2013)
Ann Allergy Asthma Immunol
, vol.110
, pp. 233-239
-
-
Lipworth, B.1
-
37
-
-
55749091647
-
Nanoparticle size and surface properties determine the protein corona with possible implications for biological impacts
-
Lundqvist M, Stigler J, Elia G, Lynch I, Cedervall T, Dawson KA. Nanoparticle size and surface properties determine the protein corona with possible implications for biological impacts. Proc Natl Acad Sci USA, 2008;105:14265-70.
-
(2008)
Proc Natl Acad Sci USA
, vol.105
, pp. 14265-14270
-
-
Lundqvist, M.1
Stigler, J.2
Elia, G.3
Lynch, I.4
Cedervall, T.5
Dawson, K.A.6
-
38
-
-
0021088070
-
Deposition of inhaled particulate matter in the upper respiratory-tract, larynx, and bronchial airways - A mathematical-description
-
Martonen T. Deposition of inhaled particulate matter in the upper respiratory-tract, larynx, and bronchial airways - A mathematical-description. J Toxicol Environ Health, 1983a;12:787-800.
-
(1983)
J Toxicol Environ Health
, vol.12
, pp. 787-800
-
-
Martonen, T.1
-
39
-
-
0020965929
-
On the fate of inhaled particles in the human - A comparison of experimental-data with theoretical computations based on a symmetric and asymmetric lung
-
Martonen T. On the fate of inhaled particles in the human - A comparison of experimental-data with theoretical computations based on a symmetric and asymmetric lung. Bull Math Biol, 1983b;45:409-24.
-
(1983)
Bull Math Biol
, vol.45
, pp. 409-424
-
-
Martonen, T.1
-
40
-
-
79551498057
-
Inhaled drug therapy for treatment of tuberculosis
-
Misra A, Hickey AJ, Rossi C, Borchard G, Terada H, Makino K, Fourie PB, Colombo P. Inhaled drug therapy for treatment of tuberculosis. Tuberculosis (Edinb), 2011;91:71-81.
-
(2011)
Tuberculosis (Edinb)
, vol.91
, pp. 71-81
-
-
Misra, A.1
Hickey, A.J.2
Rossi, C.3
Borchard, G.4
Terada, H.5
Makino, K.6
Fourie, P.B.7
Colombo, P.8
-
41
-
-
84861116576
-
The chemotherapy of tuberculosis: Past, present and future
-
Mitchison D, Davies G. The chemotherapy of tuberculosis: Past, present and future. Int J Tuberc Lung Dis, 2012;16:724-32.
-
(2012)
Int J Tuberc Lung Dis
, vol.16
, pp. 724-732
-
-
Mitchison, D.1
Davies, G.2
-
42
-
-
0033812380
-
Role of individual drugs in the chemotherapy of tuberculosis
-
Mitchison DA. Role of individual drugs in the chemotherapy of tuberculosis. Int J Tuberc Lung Dis, 2000;4:796-806.
-
(2000)
Int J Tuberc Lung Dis
, vol.4
, pp. 796-806
-
-
Mitchison, D.A.1
-
43
-
-
77952584170
-
The near future: Improving the activity of rifamycins and pyrazinamide
-
Mitchison DA, Fourie PB. The near future: Improving the activity of rifamycins and pyrazinamide. Tuberculosis (Edinb), 2010;90:177-81.
-
(2010)
Tuberculosis (Edinb)
, vol.90
, pp. 177-181
-
-
Mitchison, D.A.1
Fourie, P.B.2
-
44
-
-
84879875797
-
Dynamic development of the protein corona on silica nanoparticles: Composition and role in toxicity
-
Mortensen NP, Hurst GB, Wang W, Foster CM, Nallathamby PD, Retterer ST. Dynamic development of the protein corona on silica nanoparticles: Composition and role in toxicity. Nanoscale, 2013;5:6372-80.
-
(2013)
Nanoscale
, vol.5
, pp. 6372-6380
-
-
Mortensen, N.P.1
Hurst, G.B.2
Wang, W.3
Foster, C.M.4
Nallathamby, P.D.5
Retterer, S.T.6
-
45
-
-
34548009339
-
Inhalable microparticles containing large payload of anti-tuberculosis drugs
-
Muttil P, Kaur J, Kumar K, Yadav AB, Sharma R, Misra A. Inhalable microparticles containing large payload of anti-tuberculosis drugs. Eur J Pharm Sci, 2007;32:140-50.
-
(2007)
Eur J Pharm Sci
, vol.32
, pp. 140-150
-
-
Muttil, P.1
Kaur, J.2
Kumar, K.3
Yadav, A.B.4
Sharma, R.5
Misra, A.6
-
46
-
-
70350228508
-
Inhaled drug delivery for tuberculosis therapy
-
Muttil P, Wang C, Hickey AJ. Inhaled drug delivery for tuberculosis therapy. Pharm Res, 2009;26:2401-16.
-
(2009)
Pharm Res
, vol.26
, pp. 2401-2416
-
-
Muttil, P.1
Wang, C.2
Hickey, A.J.3
-
47
-
-
84875498895
-
The immune response in tuberculosis
-
O'Garra A, Redford PS, McNab FW, Bloom CI, Wilkinson RJ, Berry MP. The immune response in tuberculosis. Annu Rev Immunol, 2013;31:475-527.
-
(2013)
Annu Rev Immunol
, vol.31
, pp. 475-527
-
-
O'Garra, A.1
Redford, P.S.2
McNab, F.W.3
Bloom, C.I.4
Wilkinson, R.J.5
Berry, M.P.6
-
48
-
-
0033795452
-
Respirable PLGA microspheres containing rifampicin for the treatment of tuberculosis: Manufacture and characterization
-
O'Hara P, Hickey AJ. Respirable PLGA microspheres containing rifampicin for the treatment of tuberculosis: Manufacture and characterization. Pharm Res, 2000;17:955-61.
-
(2000)
Pharm Res
, vol.17
, pp. 955-961
-
-
O'Hara, P.1
Hickey, A.J.2
-
49
-
-
84872294618
-
Development of a spray-drying method for the formulation of respirable microparticles containing ofloxacin-palladium complex
-
Palazzo F, Giovagnoli S, Schoubben A, Blasi P, Rossi C, Ricci M. Development of a spray-drying method for the formulation of respirable microparticles containing ofloxacin-palladium complex. Int J Pharm, 2013;440:273-82.
-
(2013)
Int J Pharm
, vol.440
, pp. 273-282
-
-
Palazzo, F.1
Giovagnoli, S.2
Schoubben, A.3
Blasi, P.4
Rossi, C.5
Ricci, M.6
-
50
-
-
17444377960
-
Antitubercular inhaled therapy: Opportunities, progress and challenges
-
Pandey R, Khuller GK. Antitubercular inhaled therapy: Opportunities, progress and challenges. J Antimicrob Chemother, 2005a;55:430-5.
-
(2005)
J Antimicrob Chemother
, vol.55
, pp. 430-435
-
-
Pandey, R.1
Khuller, G.K.2
-
51
-
-
20444385102
-
Solid lipid particle-based inhalable sustained drug delivery system against experimental tuberculosis
-
Pandey R, Khuller GK. Solid lipid particle-based inhalable sustained drug delivery system against experimental tuberculosis. Tuberculosis (Edinb), 2005b;85:227-34.
-
(2005)
Tuberculosis (Edinb)
, vol.85
, pp. 227-234
-
-
Pandey, R.1
Khuller, G.K.2
-
52
-
-
84872791453
-
Chitosan microspheres as an alveolar macrophage delivery system of ofloxacin via pulmonary inhalation
-
Park JH, Jin HE, Kim DD, Chung SJ, Shim WS, Shim CK. Chitosan microspheres as an alveolar macrophage delivery system of ofloxacin via pulmonary inhalation. Int J Pharm, 2013;441:562-9.
-
(2013)
Int J Pharm
, vol.441
, pp. 562-569
-
-
Park, J.H.1
Jin, H.E.2
Kim, D.D.3
Chung, S.J.4
Shim, W.S.5
Shim, C.K.6
-
53
-
-
33845906339
-
Inhaling medicines: Delivering drugs to the body through the lungs
-
Patton JS, Byron PR. Inhaling medicines: Delivering drugs to the body through the lungs. Nat Rev Drug Discov, 2007;6:67-74.
-
(2007)
Nat Rev Drug Discov
, vol.6
, pp. 67-74
-
-
Patton, J.S.1
Byron, P.R.2
-
54
-
-
0029761216
-
In vitro activities of fourteen antimicrobial agents against drug susceptible and resistant clinical isolates of Mycobacterium tuberculosis and comparative intracellular activities against the virulent H37Rv strain in human macrophages
-
Rastogi N, Labrousse V, Goh KS. In vitro activities of fourteen antimicrobial agents against drug susceptible and resistant clinical isolates of Mycobacterium tuberculosis and comparative intracellular activities against the virulent H37Rv strain in human macrophages. Curr Microbiol, 1996;33:167-75.
-
(1996)
Curr Microbiol
, vol.33
, pp. 167-175
-
-
Rastogi, N.1
Labrousse, V.2
Goh, K.S.3
-
55
-
-
79960774579
-
Isoniazid proliposome powders for inhalation-preparation, characterization and cell culture studies
-
Rojanarat W, Changsan N, Tawithong E, Pinsuwan S, Chan HK, Srichana T. Isoniazid proliposome powders for inhalation-preparation, characterization and cell culture studies. Int J Mol Sci, 2011;12:4414-34.
-
(2011)
Int J Mol Sci
, vol.12
, pp. 4414-4434
-
-
Rojanarat, W.1
Changsan, N.2
Tawithong, E.3
Pinsuwan, S.4
Chan, H.K.5
Srichana, T.6
-
56
-
-
84867567038
-
Inhaled pyrazinamide proliposome for targeting alveolar macrophages
-
Rojanarat W, Nakpheng T, Thawithong E, Yanyium N, Srichana T. Inhaled pyrazinamide proliposome for targeting alveolar macrophages. Drug Deliv, 2012;19:334-45.
-
(2012)
Drug Deliv
, vol.19
, pp. 334-345
-
-
Rojanarat, W.1
Nakpheng, T.2
Thawithong, E.3
Yanyium, N.4
Srichana, T.5
-
57
-
-
84856077790
-
Aerosolized gentamicin reduces the burden of tuberculosis in a murine model
-
Roy CJ, Sivasubramani SK, Dutta NK, Mehra S, Golden NA, Killeen S, Talton JD, Hammoud BE, Didier PJ, Kaushal D. Aerosolized gentamicin reduces the burden of tuberculosis in a murine model. Antimicrob Agents Chemother, 2012;56:883-6.
-
(2012)
Antimicrob Agents Chemother
, vol.56
, pp. 883-886
-
-
Roy, C.J.1
Sivasubramani, S.K.2
Dutta, N.K.3
Mehra, S.4
Golden, N.A.5
Killeen, S.6
Talton, J.D.7
Hammoud, B.E.8
Didier, P.J.9
Kaushal, D.10
-
58
-
-
33750845387
-
In vivo, in vitro and ex vivo models to assess pulmonary absorption and disposition of inhaled therapeutics for systemic delivery
-
Sakagami M. In vivo, in vitro and ex vivo models to assess pulmonary absorption and disposition of inhaled therapeutics for systemic delivery. Adv Drug Del Rev, 2006;58:1030-60.
-
(2006)
Adv Drug del Rev
, vol.58
, pp. 1030-1060
-
-
Sakagami, M.1
-
59
-
-
84875209682
-
Capreomycin supergenerics for pulmonary tuberculosis treatment: Preparation, in vitro, and in vivo characterization
-
Schoubben A, Blasi P, Marenzoni ML, Barberini L, Giovagnoli S, Cirotto C, Ricci M. Capreomycin supergenerics for pulmonary tuberculosis treatment: Preparation, in vitro, and in vivo characterization. Eur J Pharm Biopharm, 2013;83:388-95.
-
(2013)
Eur J Pharm Biopharm
, vol.83
, pp. 388-395
-
-
Schoubben, A.1
Blasi, P.2
Marenzoni, M.L.3
Barberini, L.4
Giovagnoli, S.5
Cirotto, C.6
Ricci, M.7
-
60
-
-
33846612373
-
Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: Evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy
-
Shandil RK, Jayaram R, Kaur P, Gaonkar S, Suresh BL, Mahesh BN, Jayashree R, Nandi V, Bharath S, Balasubramanian V. Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: Evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy. Antimicrob Agents Chemother, 2007;51:576-82.
-
(2007)
Antimicrob Agents Chemother
, vol.51
, pp. 576-582
-
-
Shandil, R.K.1
Jayaram, R.2
Kaur, P.3
Gaonkar, S.4
Suresh, B.L.5
Mahesh, B.N.6
Jayashree, R.7
Nandi, V.8
Bharath, S.9
Balasubramanian, V.10
-
61
-
-
0034781469
-
Inhalable microparticles containing drug combinations to target alveolar macrophages for treatment of pulmonary tuberculosis
-
Sharma R, Saxena D, Dwivedi AK, Misra A. Inhalable microparticles containing drug combinations to target alveolar macrophages for treatment of pulmonary tuberculosis. Pharm Res, 2001;18:1405-10.
-
(2001)
Pharm Res
, vol.18
, pp. 1405-1410
-
-
Sharma, R.1
Saxena, D.2
Dwivedi, A.K.3
Misra, A.4
-
62
-
-
0034702247
-
A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis
-
Stover CK, Warrener P, Vandevanter DR, Sherman DR, Arain TM, Langhorne MH, Anderson SW, Towell JA, Yuan Y, McMurray DN, et al. A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. Nature, 2000;405:962-6.
-
(2000)
Nature
, vol.405
, pp. 962-966
-
-
Stover, C.K.1
Warrener, P.2
Vandevanter, D.R.3
Sherman, D.R.4
Arain, T.M.5
Langhorne, M.H.6
Anderson, S.W.7
Towell, J.A.8
Yuan, Y.9
McMurray, D.N.10
-
63
-
-
0034812708
-
Airways delivery of rifampicin microparticles for the treatment of tuberculosis
-
Suarez S, O'Hara P, Kazantseva M, Newcomer CE, Hopfer R, McMurray DN, Hickey AJ. Airways delivery of rifampicin microparticles for the treatment of tuberculosis. J Antimicrob Chemother, 2001a;48:431-4.
-
(2001)
J Antimicrob Chemother
, vol.48
, pp. 431-434
-
-
Suarez, S.1
O'Hara, P.2
Kazantseva, M.3
Newcomer, C.E.4
Hopfer, R.5
McMurray, D.N.6
Hickey, A.J.7
-
64
-
-
0034848118
-
Respirable PLGA microspheres containing rifampicin for the treatment of tuberculosis: Screening in an infectious disease model
-
Suarez S, O'Hara P, Kazantseva M, Newcomer CE, Hopfer R, McMurray DN, Hickey AJ. Respirable PLGA microspheres containing rifampicin for the treatment of tuberculosis: Screening in an infectious disease model. Pharm Res, 2001b;18:1315-19.
-
(2001)
Pharm Res
, vol.18
, pp. 1315-1319
-
-
Suarez, S.1
O'Hara, P.2
Kazantseva, M.3
Newcomer, C.E.4
Hopfer, R.5
McMurray, D.N.6
Hickey, A.J.7
-
65
-
-
65649147964
-
Dry powder nitroimidazopyran antibiotic PA-824 aerosol for inhalation
-
Sung JC, Garcia-Contreras L, Verberkmoes JL, Peloquin CA, Elbert KJ, Hickey AJ, Edwards DA. Dry powder nitroimidazopyran antibiotic PA-824 aerosol for inhalation. Antimicrob Agents Chemother, 2009;53:1338-43.
-
(2009)
Antimicrob Agents Chemother
, vol.53
, pp. 1338-1343
-
-
Sung, J.C.1
Garcia-Contreras, L.2
Verberkmoes, J.L.3
Peloquin, C.A.4
Elbert, K.J.5
Hickey, A.J.6
Edwards, D.A.7
-
66
-
-
0019170979
-
Generation and respiratory deposition of therapeutic aerosols
-
Swift DL. Generation and respiratory deposition of therapeutic aerosols. Am Rev Respir Dis, 1980;122:71-7.
-
(1980)
Am Rev Respir Dis
, vol.122
, pp. 71-77
-
-
Swift, D.L.1
-
67
-
-
33644617924
-
Dry powder inhaler formulation
-
Telko MJ, Hickey AJ. Dry powder inhaler formulation. Respir Care, 2005;50:1209-27.
-
(2005)
Respir Care
, vol.50
, pp. 1209-1227
-
-
Telko, M.J.1
Hickey, A.J.2
-
68
-
-
10744225450
-
Direct lung delivery of para-aminosalicylic acid by aerosol particles
-
Tsapis N, Bennett D, O'Driscoll K, Shea K, Lipp M, Fu K, Clarke R, Deaver D, Yamins D, Wright J, et al. Direct lung delivery of para-aminosalicylic acid by aerosol particles. Tuberculosis, 2003;83:379-85.
-
(2003)
Tuberculosis
, vol.83
, pp. 379-385
-
-
Tsapis, N.1
Bennett, D.2
O'Driscoll, K.3
Shea, K.4
Lipp, M.5
Fu, K.6
Clarke, R.7
Deaver, D.8
Yamins, D.9
Wright, J.10
-
69
-
-
79959366396
-
Targeting small airways in asthma: Improvement in clinical benefit?
-
Ulrik CS, Lange P. Targeting small airways in asthma: Improvement in clinical benefit? Clin Respir J, 2011;5:125-30.
-
(2011)
Clin Respir J
, vol.5
, pp. 125-130
-
-
Ulrik, C.S.1
Lange, P.2
-
71
-
-
84872859798
-
Inhaled microparticles containing clofazimine are efficacious in treatment of experimental tuberculosis in mice
-
Verma RK, Germishuizen WA, Motheo MP, Agrawal AK, Singh AK, Mohan M, Gupta P, Gupta UD, Cholo M, Anderson R, et al. Inhaled microparticles containing clofazimine are efficacious in treatment of experimental tuberculosis in mice. Antimicrob Agents Chemother, 2013;57:1050-2.
-
(2013)
Antimicrob Agents Chemother
, vol.57
, pp. 1050-1052
-
-
Verma, R.K.1
Germishuizen, W.A.2
Motheo, M.P.3
Agrawal, A.K.4
Singh, A.K.5
Mohan, M.6
Gupta, P.7
Gupta, U.D.8
Cholo, M.9
Anderson, R.10
-
72
-
-
79960252887
-
Inhaled therapies for tuberculosis and the relevance of activation of lung macrophages by particulate drug-delivery systems
-
Verma RK, Singh AK, Mohan M, Agrawal AK, Misra A. Inhaled therapies for tuberculosis and the relevance of activation of lung macrophages by particulate drug-delivery systems. Ther Deliv, 2011;2:753-68.
-
(2011)
Ther Deliv
, vol.2
, pp. 753-768
-
-
Verma, R.K.1
Singh, A.K.2
Mohan, M.3
Agrawal, A.K.4
Misra, A.5
-
73
-
-
8044225583
-
Effect of adsorbed proteins on wettability of hydrophilic and hydrophobic solids
-
Vroman L. Effect of adsorbed proteins on wettability of hydrophilic and hydrophobic solids. Nature, 1962;196:476.
-
(1962)
Nature
, vol.196
, pp. 476
-
-
Vroman, L.1
-
74
-
-
0018917567
-
Interaction of high molecular-weight kininogen, factor-XII, and fibrinogen in plasma at interfaces
-
Vroman L, Adams AL, Fischer GC, Munoz PC. Interaction of high molecular-weight kininogen, factor-XII, and fibrinogen in plasma at interfaces. Blood, 1980;55:156-9.
-
(1980)
Blood
, vol.55
, pp. 156-159
-
-
Vroman, L.1
Adams, A.L.2
Fischer, G.C.3
Munoz, P.C.4
-
75
-
-
65549165981
-
Screening for potential adjuvants administered by the pulmonary route for tuberculosis vaccines
-
Wang C, Muttil P, Lu D, Beltran-Torres AA, Garcia-Contreras L, Hickey AJ. Screening for potential adjuvants administered by the pulmonary route for tuberculosis vaccines. AAPS J, 2009;11:139-47.
-
(2009)
AAPS J
, vol.11
, pp. 139-147
-
-
Wang, C.1
Muttil, P.2
Lu, D.3
Beltran-Torres, A.A.4
Garcia-Contreras, L.5
Hickey, A.J.6
-
76
-
-
0029937191
-
Testing of Mycobacterium tuberculosis susceptibility to ethambutol, isoniazid, rifampin, and streptomycin by using Etest
-
Wanger A, Mills K. Testing of Mycobacterium tuberculosis susceptibility to ethambutol, isoniazid, rifampin, and streptomycin by using Etest. J Clin Microbiol, 1996;34:1672-6.
-
(1996)
J Clin Microbiol
, vol.34
, pp. 1672-1676
-
-
Wanger, A.1
Mills, K.2
|